{"disease":{"id":"hereditary-angioedema","name":"hereditary angioedema"},"drugs":{"marketed":[{"drug_id":"donidalorsen","indication_name":"hereditary angioedema (HAE)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dawnzera","generic_name":"DONIDALORSEN","company_name":"Ionis Pharms Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":47,"revenue":null,"mechanism":"Dawnzera works by binding to a specific messenger RNA molecule to prevent the production of a faulty protein that causes hereditary angioedema."},{"drug_id":"donidalorsen","indication_name":"hereditary angioedema (HAE)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dawnzera","generic_name":"DONIDALORSEN","company_name":"Ionis Pharms Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":47,"revenue":null,"mechanism":"Dawnzera works by binding to a specific messenger RNA molecule to prevent the production of a faulty protein that causes hereditary angioedema."},{"drug_id":"danazol","indication_name":"Hereditary Angioedema Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Danzol","generic_name":"DANAZOL","company_name":"","drug_phase":"marketed","molecular_target":"Sex hormone-binding globulin","drug_class":"Androgen [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"sebetralstat","indication_name":"hereditary angioedema (HAE)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ekterly","generic_name":"SEBETRALSTAT","company_name":"Kalvista","drug_phase":"marketed","molecular_target":"","drug_class":"Plasma Kallikrein Inhibitor [EPC]","quality_score":45,"revenue":null,"mechanism":"Ekterly works by blocking the plasma kallikrein enzyme, which is involved in the production of bradykinin, a key mediator of HAE symptoms."}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01034969","title":"Firazyr® Patient Registry (Icatibant Outcome Survey - IOS)","phase":"","overall_status":"COMPLETED","enrollment_count":1761,"lead_sponsor_name":"Shire","has_results":false},{"nct_id":"NCT05904301","title":"Armenian NAtionwide REGistry of Systemic Autoimmune and Autoinflammatory Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"Santé Arménie French-Armenian Research Center","has_results":false},{"nct_id":"NCT07293364","title":"A Study to Learn About the C1-Inhibitor Function as Diagnosis for Hereditary Angioedema","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":514,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT03472040","title":"A Long Term Safety Study of BCX7353 in Hereditary Angioedema","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":387,"lead_sponsor_name":"BioCryst Pharmaceuticals","has_results":true},{"nct_id":"NCT06573723","title":"Institutional Registry of Rare Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":380,"lead_sponsor_name":"Hospital Italiano de Buenos Aires","has_results":false},{"nct_id":"NCT04888650","title":"Assessment of the State of Health, Quality of Life and Expectations of Patients With Hereditary Angioedema","phase":"","overall_status":"COMPLETED","enrollment_count":314,"lead_sponsor_name":"University Hospital, Grenoble","has_results":false},{"nct_id":"NCT06806618","title":"HAE Burden and Crisis Management","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"University Hospital, Grenoble","has_results":false},{"nct_id":"NCT04957641","title":"A Study of the Burden of Illness and Treatment Patterns in Teenagers and Adults With Hereditary Angioedema","phase":"","overall_status":"COMPLETED","enrollment_count":221,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT03828279","title":"Global Registry to Gather Data on Natural History of Patients With Hereditary Angioedema Type I and II","phase":"","overall_status":"UNKNOWN","enrollment_count":220,"lead_sponsor_name":"HAE Global Registry Foundation","has_results":false},{"nct_id":"NCT02741596","title":"Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":212,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT04861090","title":"A Study in Teenagers and Adults With Hereditary Angioedema (HAE) Type I or Type II Who Use Lanadelumab as Long-Term Prophylaxis","phase":"","overall_status":"COMPLETED","enrollment_count":207,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT07001280","title":"A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE)","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"CSL Behring","has_results":false},{"nct_id":"NCT04057131","title":"FIRAZYR General Drug Use-Results Survey (Japan)","phase":"","overall_status":"COMPLETED","enrollment_count":179,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT04739059","title":"Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":171,"lead_sponsor_name":"CSL Behring","has_results":false},{"nct_id":"NCT03845400","title":"A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North America","phase":"","overall_status":"COMPLETED","enrollment_count":168,"lead_sponsor_name":"Shire","has_results":false},{"nct_id":"NCT05397431","title":"A Survey of Lanadelumab in Participants With Hereditary Angioedema","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":155,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT03697187","title":"Patient Registry to Evaluate the Real-world Safety of Ruconest®","phase":"","overall_status":"COMPLETED","enrollment_count":152,"lead_sponsor_name":"Pharming Technologies B.V.","has_results":false},{"nct_id":"NCT00997204","title":"EASSI - Evaluation of the Safety of Self-Administration With Icatibant","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":151,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT00456508","title":"Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":147,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT00462709","title":"Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":146,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT05505916","title":"An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":145,"lead_sponsor_name":"KalVista Pharmaceuticals, Ltd.","has_results":false},{"nct_id":"NCT04130191","title":"A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II","phase":"","overall_status":"COMPLETED","enrollment_count":140,"lead_sponsor_name":"Shire","has_results":false},{"nct_id":"NCT05259917","title":"A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":136,"lead_sponsor_name":"KalVista Pharmaceuticals, Ltd.","has_results":true},{"nct_id":"NCT06343779","title":"Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":134,"lead_sponsor_name":"Pharvaris Netherlands B.V.","has_results":false},{"nct_id":"NCT02316353","title":"A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":126,"lead_sponsor_name":"CSL Behring","has_results":true},{"nct_id":"NCT02586805","title":"Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":125,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT03485911","title":"Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":121,"lead_sponsor_name":"BioCryst Pharmaceuticals","has_results":true},{"nct_id":"NCT06346899","title":"A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China","phase":"","overall_status":"COMPLETED","enrollment_count":115,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT00438815","title":"Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":113,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT05178355","title":"A Single and Multiple Doses Safety, Tolerability, Pharmacokinetics and Food Effect Study of KVD824 in Healthy Volunteers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":108,"lead_sponsor_name":"KalVista Pharmaceuticals, Ltd.","has_results":false},{"nct_id":"NCT07218393","title":"A Study About the Diagnosis and Management of Hereditary Angioedema (HAE) in Egypt","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT00912093","title":"A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":98,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT00457015","title":"Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":96,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT02892682","title":"The Role of the Coagulation Pathways in Recurrent Angioedema","phase":"NA","overall_status":"TERMINATED","enrollment_count":96,"lead_sponsor_name":"University Hospital, Montpellier","has_results":false},{"nct_id":"NCT05139810","title":"OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":91,"lead_sponsor_name":"Ionis Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT00262080","title":"Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":91,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT07428499","title":"Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":90,"lead_sponsor_name":"ADARx Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT06960213","title":"STOP-HAE: A Phase 3 Study of ADX-324 in HAE","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":90,"lead_sponsor_name":"ADARx Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT07009262","title":"A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE Attacks","phase":"","overall_status":"COMPLETED","enrollment_count":88,"lead_sponsor_name":"KalVista Pharmaceuticals, Ltd.","has_results":false},{"nct_id":"NCT05489640","title":"A Study in Adults With Hereditary Angioedema (HAE) Who Currently Receive Icatibant at Home","phase":"","overall_status":"COMPLETED","enrollment_count":85,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT00500656","title":"Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema (HAE)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":85,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT04349800","title":"A Single Dose Safety, Tolerability, Pharmacokinetic and Food Effect Study of KVD900 (Sebetralstat) in Healthy Volunteers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":84,"lead_sponsor_name":"KalVista Pharmaceuticals, Ltd.","has_results":false},{"nct_id":"NCT04208412","title":"A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or II","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":84,"lead_sponsor_name":"KalVista Pharmaceuticals, Ltd.","has_results":true},{"nct_id":"NCT00289211","title":"C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":83,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT01541423","title":"A European Post-Authorisation Observational Study Of Patients With Hereditary Angioedema","phase":"","overall_status":"COMPLETED","enrollment_count":83,"lead_sponsor_name":"Shire","has_results":false},{"nct_id":"NCT01059526","title":"Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema","phase":"","overall_status":"COMPLETED","enrollment_count":81,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT01826916","title":"EDEMA2: Evaluation of DX-88's Effect in Mitigating Angioedema","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":77,"lead_sponsor_name":"Shire","has_results":false},{"nct_id":"NCT02584959","title":"Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":75,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT04618211","title":"Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":74,"lead_sponsor_name":"Pharvaris Netherlands B.V.","has_results":true},{"nct_id":"NCT04656418","title":"CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"CSL Behring","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}